Should I take Mitotane for ten years after adrenal cancer surgery?

There is extensive clinical discussion about whether long-term use of Mitotane (Mitotane) for up to ten years is needed after surgery for adrenocortical cancer (ACC; adrenal cancer). Mitotane is a targeted drug that specifically targets adrenocortical function. Its main function is to inhibit tumor-related metabolism and adrenocortical function, thereby limiting the growth of residual tumor cells. Therefore, it is often regarded as one of the core options for maintenance treatment in patients with high risk of recurrence. However, ten years of continuous medication is not suitable for all patients. Whether to take it for a long time should be comprehensively judged based on the risk of postoperative recurrence, blood drug concentration, patient tolerance and long-term follow-up results.

Mitotane treatment regimens are individualized based on the patient's risk stratification and disease progression. High-risk patients usually require longer maintenance treatment, while low- and medium-risk patients can gradually adjust the dose or even discontinue the drug based on imaging and hormone monitoring results. Long-term medication not only helps delay recurrence, but also maintains stable hormone levels, thereby improving postoperative quality of life.

Mitotane has a long half-life and significant accumulation. Long-term use requires regular testing of blood concentration and liver and kidney function to ensure that the drug is within the effective range without causing serious adverse reactions. Although there are case reports on taking medication for ten years, they more reflect the importance of individualized management. Patients need to maintain standardized follow-up during long-term medication, including regular imaging evaluation, hormone level monitoring and physical symptom observation, in order to early detect potential adverse reactions or signs of recurrence.

In short, taking mitotane for ten years after surgery can theoretically achieve long-term disease control, but the specific plan must be based on the patient's own risks and tolerance and formulated after evaluation by a doctor to ensure that the treatment is both effective and safe. Long-term follow-up and individualized adjustments are key to maximizing the value of mitotane.

Reference materials:https://go.drugbank.com/drugs/DB00648